Spectral AI, Inc. develops artificial intelligence medical diagnostics for wound care, with the DeepView System as its principal platform for burn-wound assessment. DeepView combines multispectral imaging with a proprietary AI algorithm to evaluate the healing potential of burn wounds and provide a binary prediction on whether tissue is likely to heal within a specified period.
Recurring news about Spectral AI covers DeepView presentations at burn-care medical meetings, BARDA funding for burn imaging technology, FDA De Novo 510(k) activity, financial results, commercialization preparation, stockholder meetings and executive appointments. Company updates also describe research and development revenue tied to government-supported development work and governance matters associated with its Nasdaq-listed common stock.
Spectral AI (Nasdaq: MDAI) will report its third-quarter 2026 financial results after the market closes on November 10, 2026. The results cover the quarter ended September 30, 2026. A conference call to discuss the results will follow at 5:00 pm Eastern Time that day, with a simultaneous webcast available through the company’s investor relations Events page.
Spectral AI (Nasdaq: MDAI) showcased its DeepView burn assessment system at the ACEP Scientific Assembly, held October 5–8, 2026, in Chicago.
The event drew an estimated 7,000 attendees. DeepView is a non-invasive device that combines imaging and artificial intelligence to assess burn wounds’ healing potential. It received FDA De Novo classification in May 2026. The company identified emergency care as a priority market for commercialization and used the assembly to engage with emergency department decision makers.
Spectral AI (MDAI) submitted an application for additional Medicare inpatient payments for its DeepView System through an alternative reimbursement pathway.
The New Technology Add-On Payment (NTAP) program provides extra hospital payments for qualifying cases involving new technologies. DeepView assesses burn-wound healing potential and received FDA De Novo marketing authorization in May 2026. Its Breakthrough Device Designation and FDA authorization enabled the reimbursement application.
Spectral AI expects a CMS decision in August 2027. If approved, payment status would generally begin in October 2027 and continue for approximately three years. Additional payments are generally limited to approximately 65% of the technology's estimated cost and remain subject to CMS requirements. The company said reimbursement could help offset hospitals' incremental costs and reduce adoption barriers.
Spectral AI (MDAI) completed the first site initiation visit for a DeepView clinical study supporting potential burn-label expansion.
The visit at Pinderfields Hospital in Wakefield, UK, led by Dr. Preetha Muthayya, marks the study’s operational launch and enables patient enrollment after completion of applicable site-readiness requirements. Spectral AI intends the study to support expansion of its FDA-cleared burn indication to the head, hands and feet.
The prospective study is expected to enroll adults and children with qualifying thermal burns across multiple UK sites. Participants will be imaged within 72 hours of injury, with healing assessed through 21 days. Images will support algorithm training and independent validation. DeepView will be used in a blinded, observational capacity, not to direct care. The company expects completion in 2027.
Spectral AI (MDAI) will present research on AI-assisted burn-wound assessment at ACS Clinical Congress 2026 in Washington, DC.
The congress runs September 26–29. James H. Holmes IV, director of the Burn Center at Atrium Health Wake Forest Baptist Medical Center, will lead the presentation on training and validating a multispectral imaging device for burn-wound evaluation. The research concerns Spectral AI’s DeepView system, which received FDA De Novo Classification in May 2026.
Spectral AI (MDAI) highlighted its DeepView® System for Burn Indication at the Southern Regional Burn Conference held September 10-12, 2026 in Williamsburg, Virginia, where key opinion leaders presented research on AI-assisted multispectral imaging for burn assessment.
The DeepView System is described as a non-invasive, predictive device that assesses healing potential within burn wounds by combining multispectral imaging with a proprietary AI algorithm. It was granted De Novo Classification by the U.S. FDA in May 2026 and received initial UKCA authorization in the United Kingdom in February 2024. The system delivers image acquisition in 0.2 seconds, with AI processing in about 20–25 seconds, and is trained on over 340 billion pixels of burn wound image data. Spectral AI also plans further DeepView-focused KOL presentations at the Midwest and Northeast Region Burn Conferences in October and November 2026.
Spectral AI (Nasdaq: MDAI) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14–16, 2026. CEO Vincent Capone and CFO David McGuire plan to highlight the company’s growth strategy and readiness for a 2026 commercial launch of its FDA De Novo–cleared DeepView® System for Burn Indication, which received clearance in May 2026. The presentation is scheduled for Monday, September 14, 2026 at 4:00 pm ET, with a live webcast available via the Investors section of Spectral AI’s website, and options to request one-on-one meetings through H.C. Wainwright or the company’s investor relations firm.
Spectral AI (Nasdaq: MDAI) reported Q2 2026 results and outlined progress toward first commercial sales of its DeepView® System for burn indication by year end 2026. According to Spectral AI, De Novo FDA clearance in May 2026 authorizes U.S. commercial distribution, supported by a $31.7 million BARDA advanced funding award and completion of key Department of Defense milestones.
Q2 2026 research & development revenue was $3.5 million versus $5.1 million, with gross margin of 31.6% versus 45.2%, reflecting cost-share under the BARDA follow-on phase and mix. Operating expenses rose 23.2% to $5.4 million. Net loss narrowed to $4.2 million (−$0.13 per share) from $8.0 million, mainly due to a favorable warrant liability revaluation. Cash was $14.0 million at June 30, 2026, after drawing $6.5 million from an Avenue Capital credit facility. The company reiterated 2026 revenue guidance of approximately $18.5 million, largely driven by BARDA contract development work.
Spectral AI (Nasdaq: MDAI) will release its 2026 second quarter financial results for the period ended June 30, 2026 on Tuesday, August 11, 2026, after the close of the Nasdaq market. A conference call to discuss the results is scheduled for 5:00 p.m. Eastern Time the same day, with U.S. and international dial-in numbers and a simultaneous webcast available via the Events section of the company’s investor relations website.
Spectral AI (Nasdaq:MDAI) appointed industry veteran Darcy Bajko as Chief Commercial Officer, effective July 31, 2026. She will lead global commercialization of the FDA De Novo–cleared DeepView® System for burn indication as the company pivots from product development to commercial execution.
DeepView is a non-invasive, AI-driven imaging device that rapidly predicts burn wound healing potential to guide treatment decisions.